MNG1163
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.486
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.422
- IL6_JAK_STAT3_SIGNALING+0.404
- INFLAMMATORY_RESPONSE+0.380
- MYOGENESIS+0.348
- UV_RESPONSE_UP+0.348
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.335
- COAGULATION+0.334
- APOPTOSIS+0.269
- ESTROGEN_RESPONSE_LATE+0.246
Top 10 suppressed
- PROTEIN_SECRETION-0.405
- E2F_TARGETS-0.343
- G2M_CHECKPOINT-0.300
- MITOTIC_SPINDLE-0.297
- NOTCH_SIGNALING-0.193
- MTORC1_SIGNALING-0.143
- UV_RESPONSE_DN-0.136
- UNFOLDED_PROTEIN_RESPONSE-0.095
- MYC_TARGETS_V1-0.083
- PEROXISOME-0.083
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 82996 | EPN | Supratentorial EPN | 0.861 |
| 2 | SRR1388979 | GTEX | — | 0.859 |
| 3 | BS_J8VX4D17 | EPN | Posterior Fossa EPN | 0.857 |
| 4 | MNG1090 | — | — | 0.848 |
| 5 | SRR820883 | GTEX | — | 0.848 |
| 6 | MNG1261 | — | — | 0.842 |
| 7 | SRR1489821 | GTEX | — | 0.842 |
| 8 | BS_J8VX4D17 | Posterior Fossa Ependymoma | — | 0.840 |
| 9 | BS_WWKNJSJ5 | ATRT | — | 0.837 |
| 10 | SRR1328487 | GTEX | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.486 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.422 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.404 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYOGENESIS | 0.348 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.348 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.335 | Inavolisib | — uncovered |
| COAGULATION | 0.334 | Binimetinib | — uncovered |
| APOPTOSIS | 0.269 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.246 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.243 | Idelalisib | — uncovered |
| HYPOXIA | 0.227 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.226 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.226 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.213 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.202 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.183 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.181 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |